Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1

Archives of Disease in Childhood

Volumn 94, Issue 12, 2009, Pages 981-982

  Sakaguchi, S ^a   Garcia Bournissen, F ^a   Kim, R ^b   Schwarz, U I ^b   Nathan, P C ^a   Ito, Shinya ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DNA; GLUCURONOSYLTRANSFERASE 1A1; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; ORGANIC ANION TRANSPORTER 2; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CAPILLARY ELECTROPHORESIS; CASE REPORT; CHILD; CONSTIPATION; DNA EXTRACTION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; NASOPHARYNX CANCER; NEUTROPENIA; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SCHOOL CHILD; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCURONOSYLTRANSFERASE; HUMANS; NASOPHARYNGEAL NEOPLASMS; NEUTROPENIA; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RHABDOMYOSARCOMA, ALVEOLAR;

EID: 73449131555     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2009.163089     Document Type: Article

References (12)

1. Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2007;25:4622-7.
2. Kim TW, Innocenti F. Insights, challenges, and future directions in irinogenetics. Ther Drug Monit 2007;29:265-70.
3. Nozawa T, Minami H, Sugiura S, et al. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005;33:434-9.
4. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
5. Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts irinotecaninduced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008;112:1932-40.
6. Xiang X, Jada SR, Li HH, et al. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics 2006;16:683-91.
7. Takane H, Miyata M, Burioka N, et al. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit 2007;29:666-8.
8. Takane T, Kawamoto K, Sasaki T, et al. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/ *15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol 2009;63:1165-9.
9. de Jong FA, van der Bol JM, Mathijssen RH, et al. Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther 2008;84:254-62.
10. Liu JY, Qu K, Sferruzza AD, et al. Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals. Anticancer Drugs 2007;18:693-6.
11. Stewart CF, Panetta JC, O'Shaughnessy MA, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007;25:2594-600.
12. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008;9:19-33.